Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 805 clinical trials
Tissue Retractors for Radiation Therapy of Head and Neck Tumors

The rate of therapy-associated side effects during and after radiotherapy of head and neck tumors is essential. The most effective approach to reducing acute toxicity is to cut out healthy tissue from the radiation field. The distance between the tumor and normal tissue can be individually increased using personalized, 3D …

head and neck cancer
neck tumor
head and neck neoplasms
dental caries
tumour resection
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects

The primary objective of the study was to assess investigate the pharmacokinetic effects of Apatinib Mesylate on CYP2C8 Substrate Repaglinide or CYP2B6 Substrate Bupropion and metabolite Hydroxy bupropion in Advanced solid tumor subjects. The secondary objective of the study was to assess the safety of Apatinib or/and Repaglinide and Bupropion.

mitomycin
colony stimulating factor
apatinib
cytostatic drugs
targeted therapy
  • 0 views
  • 16 Feb, 2024
  • 1 location
1 A Study of LCAR-G08 in Subjects With Advanced Gastrointestinal Tumors Expressing Guanylyl Cyclase C (GCC)

This is a phase 1, single-arm, open-label, dose escalation and expansion study of LCAR-G08 in adult subjects with advanced gastrointestinal tumors expressing guanylyl cyclase C (GCC).1

  • 0 views
  • 16 Jan, 2024
A Study of SBT6050 in Patients With Advanced HER2 Expressing Solid Tumors

A first-in-human (FIH) study using SBT6050 in HER2 expressing advanced malignancies

cancer
solid tumor
solid tumour
measurable disease
pembrolizumab
  • 0 views
  • 16 Feb, 2024
  • 3 locations
Impact of a Resource-based Life Review Intervention on Advanced Cancer Patients

The main objective of the present study is to evaluate the effects of the Revie intervention on the self-esteem of patients diagnosed with an advanced cancer. A pragmatic, two-arm parallel-group, waitlist randomized controlled trial is conducted. The study takes place in the oncology department of the University Hospitals of Geneva …

cancer
advanced cancer
  • 0 views
  • 16 Feb, 2024
  • 1 location
Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors

An ascending dose study in patients with solid tumors to evaluate the safety, tolerability, pharmacodynamics and efficacy of APG-1387 in combination with toripalimab. A phase II study of 3 cohorts will be included.

brain metastasis
metastasis
hair thinning
growth factor
antineoplastic
  • 0 views
  • 16 Feb, 2024
  • 1 location
Study of AMG 650 in Adult Participants With Advanced Solid Tumors

To evaluate the safety and tolerability of AMG 650 in adult participants and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).

  • 0 views
  • 16 Feb, 2024
  • 3 locations
Fuzheng Yiliu-1010

Real world study was used to evaluate the therapeutic effect of Fuzheng anti-tumor therapy on colorectal cancer patients in stage II and III after surgery and standard chemotherapy, and the prediction model of dominant population of Fuzheng anti-tumor therapy was constructed by using real-world data and gene expression profile data.

  • 0 views
  • 05 Aug, 2020
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors

This is a first-in-human, open-label, multi-center, Phase 1/2, dose-escalation study with expansion cohorts to evaluate NM21-1480 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose, define the pharmacokinetics, to explore the pharmacodynamics, and to obtain preliminary evidence of the clinical activity in adult patients …

melanoma
adenocarcinoma
lung cancer
urothelial carcinoma
renal cell carcinoma
  • 0 views
  • 16 Feb, 2024
  • 4 locations
A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors

The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) and maximum tolerated dose (MTD) of JNJ-70218902 in Part 1, and to determine the safety of JNJ-70218902 RP2D(s) in Part 2.

gnrh
prostate cancer
adenocarcinoma
gonadotropin releasing hormone
castration-resistant prostate cancer
  • 0 views
  • 16 Feb, 2024
  • 7 locations